Bendamustine Hydrochloride/Rituximab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBendamustine Hydrochloride/Rituximab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAlkylating agentsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effects +[6] 
TargetsB-lymphocyte antigen CD20DNA
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes RituximabBendamustine Hydrochloride
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies1globe Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active Companies1globe Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A